ABSTRACT
BACKGROUND: Management of breast cancer is increased by late diagnoses. OBJECTIVE: To analyse direct costs of breast cancer in early and advanced stage in a third level medical facility at Mexican Social Security Institute. METHOD: Observational study, direct costs of care in breast cancer in initial and advanced clinical stages are compared. Variables analysed were laboratory and diagnostic imaging studies, drugs, as well as hospitalization costs. The evaluated period included from the first care to the completion of the treatment. Costs were determined according to the table of Unit Costs by Level of Medical Care for the year 2019 of the Mexican Social Security Institute. Student's t test was used to determinate differences between groups, as well as descriptive statistics. RESULTS: The advanced stage compared to the initial stage, causes a greater number of laboratory-cabinet studies, surgeries, day/bed and interconsultations. The average cost of breast cancer care per patient is $99,280.36 (US$5,230.78) and $148,023.60 (US$7,789.92) for the initial and advanced stages, respectively (p = 0.024). CONCLUSIONS: Cost of medical attention in the initial stage is lower than that of the advanced stage.
ANTECEDENTES: Los diagnósticos tardíos elevan los costes de atención del cáncer de mama. OBJETIVO: Analizar los costes directos de la atención del cáncer de mama en etapa temprana y avanzada en el tercer nivel de atención en el Instituto Mexicano del Seguro Social (IMSS). MÉTODO: Estudio observacional que compara los costes directos de atención en cáncer de mama en estadios clínicos inicial y avanzado. Los datos analizados fueron estudios de laboratorio, gabinete, tratamiento y hospitalización. El tiempo evaluado incluyó desde la primera atención hasta la finalización del primer tratamiento. Se determinaron los costes de acuerdo con la tabla de Costes Unitarios por Nivel de Atención Médica para el año 2019 del IMSS. Se utilizó la prueba t de Student para diferencias entre grupos, así como estadística descriptiva. RESULTADOS: El estadio avanzado, comparado con el estadio inicial, ocasiona un número mayor de estudios de laboratorio-gabinete, cirugías, día/cama e interconsultas. El coste promedio de la atención del cáncer de mama por paciente es $99,280,36 (US$5,230.78) y $148,023.60 (US$7,789.92) para los estadios inicial y avanzado, respectivamente (p = 0.024). CONCLUSIONES: El coste de la atención médica del estadio inicial es menor que el del estadio avanzado.
Subject(s)
Breast Neoplasms , Humans , Female , Mexico , Retrospective StudiesABSTRACT
Background: The testicular cancer prevails in the third decade of life, the care cost increases with higher staging of the disease. Objective: Compare the direct costs of medical and surgical attention for testicular cancer in early and advanced stages in a Third Level Medical Facility. Material and Methods: Process study, direct costs of medical attention are evaluated. Number of laboratory studies, imaging studies, and medical and surgical treatment were analyzed. The patients were divided into 2 groups: group 1 early stages and group 2 advanced stages. Mann Whitney U test was used for the difference between groups. Results: There were 10 patients in each group, Group 1: 8 (80%) seminomas and 2 (20%) non-seminoma, Group 2: 4 (40%) seminomas and 6 (60%) non-seminomas. The average cost of care in Group 2 is higher than in Group 1, 288,827.90 and 145,911.70 Mexican pesos respectively (p=0.00578). Conclusions: The direct cost of medical attention is higher in the advanced stages compared to the early stages (AU)
Objetivo: Comparar los costes directos de atenciónmédica y quirúrgica del cáncer testicular en etapa tempranay avanzada en un hospital de tercer nivel.Material y Métodos: Estudio de proceso, se evalúancostes directos de atención médica. Se analizaron númerode estudios de laboratorio, gabinete y tratamiento médico yquirúrgico. Los pacientes se dividieron en 2 grupos: grupo1 estadios tempranos y grupo 2 estadios avanzados. Se utilizó la prueba de U de Mann Whitney para diferencia entregrupos.Resultados: Fueron 10 pacientes en cada grupo,Grupo 1: 8 (80%) seminomas y 2 (20%) no seminomas,Grupo 2: 4 (40%) seminomas y 6 (60%) no seminomas. Elcoste promedio de atención en el Grupo 2 es mayor que enel Grupo 1, $288,827.90 y $145,911.70 pesos mexicanosrespectivamente (p=0.00578).Conclusiones: El coste directo de atención médica esmayor en los estadios avanzados comparado con los estadios tempranos. (AU)
Subject(s)
Humans , Male , Young Adult , Adult , Middle Aged , Health Care Costs , Social Security/statistics & numerical data , Testicular Neoplasms/economics , Testicular Neoplasms/surgery , Neoplasm Staging , Cohort Studies , MexicoABSTRACT
OBJECTIVES: There is no updated information on epidemiology and cost of management of non infectious uveitis (NIU) in Spain. This study assessed the frequency of various types of uveítis as well as associated costs of resources used in their management. MATERIAL AND METHOD: NIU epidemiological data and direct costs were collected from a literature search. This was complemented with consensus information from 2 expert panel meetings and data from questionnaires to ophthalmologists and rheumatologists, experts on these conditions. Healthcare resources costs were obtained from the Oblikue database, from a medical society and from approved drug prices in Spain. RESULTS: During 2011 the estimate number of NIU was 9,398 (45% male, 70% aged 16-65 years). Incidence per type of uveitis was: acute anterior uveitis (AAU) 55%; posterior uveitis (PU) and pan-uveitis (PanU) 15% each; adult chronic anterior uveitis, paediatric chronic anterior uveitis and intermediate uveitis 5% each. Among total costs (77,834,282.10), initial drug therapy was the highest (43,602,359.29), followed by surgical treatment of complications (8,367,420.43). With respect to types of uveitis, PanU (26,692,948.29), PU (22,283,330.50) and AAU (14,336,755.38) showed the highest associated costs. CONCLUSIONS: Non infectious uveitis is associated to high costs in Spain, both in its diagnosis and in its treatment. Early diagnosis and treatment should allow for substantial savings for the National Health System.
